High-resolution genomic mapping reveals consistent amplification of the fibroblast growth factor receptor substrate 2 gene in well-differentiated and dedifferentiated liposarcoma

Genes Chromosomes and Cancer

Volumn 50, Issue 11, 2011, Pages 849-858

  Wang, Xiaoke ^a   Asmann, Yan W ^a   Erickson Johnson, Michele R ^a   Oliveira, Jennifer L ^a   Zhang, Hongying ^b   Moura, Rafael D ^c   Lazar, Alexander J ^d   Lev, Dina ^d   Bill, Katelynn ^d   Lloyd, Ricardo V ^e   Yaszemski, Michael J ^a   Maran, Avudaiappan ^a   Oliveira, Andre M ^a  

^a MAYO CLINIC   (United States)

^b SICHUAN UNIVERSITY   (China)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d UNIVERSITY OF TEXAS   (United States)

^e UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYPEPTIDASE; CARBOXYPEPTIDASE M; FAT; FIBROBLAST GROWTH FACTOR RECEPTOR 2; MESSENGER RNA; PROTEIN MDM2; UNCLASSIFIED DRUG;

ARTICLE; CHROMOSOME 12; CONTROLLED STUDY; COPY NUMBER VARIATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE MAPPING; GENE OVEREXPRESSION; GENE TARGETING; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; LIPOMA; LIPOSARCOMA; PRIORITY JOURNAL; PROADIPOCYTE; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; UPREGULATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CELL DIFFERENTIATION; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 12; DNA COPY NUMBER VARIATIONS; GENE AMPLIFICATION; GPI-LINKED PROTEINS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LIPOSARCOMA; MEMBRANE PROTEINS; METALLOENDOPEPTIDASES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHORYLATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-MDM2; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, FIBROBLAST GROWTH FACTOR; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SIGNAL TRANSDUCTION;

EID: 80052663689     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20906     Document Type: Article

References (36)

1. Barretina J, Taylor BS, Banerji S, Ramos AH, Lagos-Quintana M, Decarolis PL, Shah K, Socci ND, Weir BA, Ho A, Chiang DY, Reva B, Mermel CH, Getz G, Antipin Y, Beroukhim R, Major JE, Hatton C, Nicoletti R, Hanna M, Sharpe T, Fennell TJ, Cibulskis K, Onofrio RC, Saito T, Shukla N, Lau C, Nelander S, Silver SJ, Sougnez C, Viale A, Winckler W, Maki RG, Garraway LA, Lash A, Greulich H, Root DE, Sellers WR, Schwartz GK, Antonescu CR, Lander ES, Varmus HE, Ladanyi M, Sander C, Meyerson M, Singer S. 2010. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet 42: 715-721.
2. Berner JM, Forus A, Elkahloun A, Meltzer PS, Fodstad O, Myklebost O. 1996. Separate amplified regions encompassing CDK4 and MDM2 in human sarcomas. Gene Chromosomes Cancer 17: 254-259.
3. Brummer T, Schmitz-Peiffer C, Daly RJ. 2010. Docking proteins. FEBS J 277: 4356-4369.
4. Chibon F, Mariani O, Derré J, Malinge S, Coindre JM, Guillou L, Lagacé R, Aurias A. 2002. A subgroup of malignant fibrous histiocytomas is associated with genetic changes similar to those of well-differentiated liposarcomas. Cancer Genet Cytogenet 139: 24-29.
5. Dei Tos AP, Doglioni C, Piccinin S, Sciot R, Furlanetto A, Boiocchi M, Dal Cin P, Maestro R, Fletcher CD, Tallini G. 2000. Coordinated expression and amplification of the MDM2, CDK4, and HMGI-C genes in atypical lipomatous tumours. J Pathol 190: 531-536.
6. Di Palma S, Lambros MB, Savage K, Jones C, Mackay A, Dexter T, Iravani M, Fenwick K, Ashworth A, Reis-Filho JS. 2007. Oncocytic change in pleomorphic adenoma: Molecular evidence in support of an origin in neoplastic cells. J Clin Pathol 60: 492-499.
7. Erickson-Johnson MR, Seys AR, Roth CW, King AA, Hulshizer RL, Wang X, Asmann YW, Lloyd RV, Jacob EK, Oliveira AM. 2009. Carboxypeptidase M: A biomarker for the discrimination of well-differentiated liposarcoma from lipoma. Mod Pathol 22: 1541-1547.
8. Fischer U, Keller A, Leidinger P, Deutscher S, Heisel S, Urbschat S, Lenhof HP, Meese E. 2008. A different view on DNA amplifications indicates frequent, highly complex, and stable amplicons on 12q13-21 in glioma. Mol Cancer Res 6: 576-584.
9. Fletcher C DM, Unni KK, Mertens F. 2002. World health organization classification of tumours pathology and genetics of tumours of soft tissue and bone. Lyon: IARC Press. p. 35-46.
10. Fritz B, Schubert F, Wrobel G, Schwaenen C, Wessendorf S, Nessling M, Korz C, Rieker RJ, Montgomery K, Kucherlapati R, Mechtersheimer G, Eils R, Joos S, Lichter P. 2002. Microarray-based copy number and expression profiling in dedifferentiated and pleomorphic liposarcoma. Cancer Res 62: 2993-2998.
11. Gotoh N. 2008. Regulation of growth factor signaling by FRS2 family docking/scaffold adaptor proteins. Cancer Sci 99: 1319-1325.
12. Hadari YR, Kouhara H, Lax I, Schlessinger J. 1998. Binding of Shp2 tyrosine phosphatase to FRS2 is essential for fibroblast growth factor-induced PC12 cell differentiation. Mol Cell Biol 18: 3966-3973.
13. Horvai AE, DeVries S, Roy R, O'Donnell RJ, Waldman F. 2009. Similarity in genetic alterations between paired well-differentiated and dedifferentiated components of dedifferentiated liposarcoma. Mod Pathol 22: 1477-1488.
14. Italiano A, Bianchini L, Keslair F, Bonnafous S, Cardot-Leccia N, Coindre JM, Dumollard JM, Hofman P, Leroux A, Mainguené C, Peyrottes I, Ranchere-Vince D, Terrier P, Tran A, Gual P, Pedeutour F. 2008. HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon. Int J Cancer 122: 2233-2241.
15. Italiano A, Bianchini L, Gjernes E, Keslair F, Ranchere-Vince D, Dumollard JM, Haudebourg J, Leroux A, Mainguené C, Terrier P, Chibon F, Coindre JM, Pedeutour F. 2009. Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas. Clin Cancer Res 15: 5696-5703.
16. Jin Z, Lahat G, Korchin B, Nguyen T, Zhu QS, Wang X, Lazar AJ, Trent J, Pollock RE, Lev D. 2008. Midkine enhances soft-tissue sarcoma growth: A possible novel therapeutic target. Clin Cancer Res 14: 5033-5042.
17. Johnson JE, Gettings EJ, Schwalm J, Pei J, Testa JR, Litwin S, von Mehren M, Broccoli D. 2007. Whole-genome profiling in liposarcomas reveals genetic alterations common to specific telomere maintenance mechanisms. Cancer Res 67: 9221-9228.
18. Medeiros F, Erickson-Johnson MR, Keeney GL, Clayton AC, Nascimento AG, Wang X, Oliveira AM. 2007. Frequency and characterization of HMGA2 and HMGA1 rearrangements in mesenchymal tumors of the lower genital tract. Genes Chromosomes Cancer 46: 981-990.
19. Mejia-Guerrero S, Quejada M, Gokgoz N, Gill M, Parkes RK, Wunder JS, Andrulis IL. 2010. Characterization of the 12q15 MDM2 and 12q13-14 CDK4 amplicons and clinical correlations in osteosarcoma. Genes Chromosomes Cancer 49: 518-525.
20. Melillo RM, Santoro M, Ong SH, Billaud M, Fusco A, Hadari YR, Schlessinger J, Lax I. 2001. Docking protein FRS2 links the protein tyrosine kinase RET and its oncogenic forms with the mitogen-activated protein kinase signaling cascade. Mol Cell Biol 21: 4177-4187.
21. Montagut C and Settleman J. 2009. Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett 283: 125-134.
22. Müller CR, Paulsen EB, Noordhuis P, Pedeutour F, Saeter G, Myklebost O. 2007. Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A. Int J Cancer 121: 199-205.
23. Nilbert M, Rydholm A, Mitelman F, Meltzer PS, Mandahl N. 1995. Characterization of the 12q13-15 amplicon in soft tissue tumors. Cancer Genet Cytogenet 83: 32-36.
24. Pedeutour F, Suijkerbuijk RF, Forus A, Van Gaal J, Van de Klundert W, Coindre JM, Nicolo G, Collin F, Van Haelst U, Huffermann K, Turc-Care C. 1994. Complex composition and co-amplification of SAS and MDM2 in ring and giant rod marker chromosomes in well-differentiated liposarcoma. Genes Chromosomes Cancer 10: 85-94.
25. Pedeutour F, Forus A, Coindre JM, Berner JM, Nicolo G, Michiels JF, Terrier P, Ranchere-Vince D, Collin F, Myklebost O, Turc-Carel C. 1999. Structure of the supernumerary ring and giant rod chromosomes in adipose tissue tumors. Genes Chromosomes Cancer 24: 30-41.
26. Peng T, Zhang P, Liu J, Nguyen T, Bolshakov S, Belousov R, Young ED, Wang X, Brewer K, López-Terrada DH, Oliveira AM, Lazar AJ, Lev D. 2011. An experimental model for the study of well-differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors. Lab Invest 91: 392-403.
27. Persson F, Olofsson A, Sjögren H, Chebbo N, Nilsson B, Stenman G, Aman P. 2008. Characterization of the 12q amplicons by high-resolution, oligonucleotide array CGH and expression analyses of a novel liposarcoma cell line. Cancer Lett 260: 37-47.
28. Ranzi V, Meakin SO, Miranda C, Mondellini P, Pierotti MA, Greco A. 2003. The signaling adapters fibroblast growth factor receptor substrate 2 and 3 are activated by the thyroid TRK oncoproteins. Endocrinology 144: 922-928.
29. Sato T, Gotoh N. 2009. The FRS2 family of docking/scaffolding adaptor proteins as therapeutic targets of cancer treatment. Expert Opin Ther Targets 13: 689-700.
30. Shangary S, Wang S. 2009. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: A novel approach for cancer therapy. Annu Rev Pharmacol Toxicol 49: 223-241.
31. Singer S, Socci ND, Ambrosini G, Sambol E, Decarolis P, Wu Y, O'Connor R, Maki R, Viale A, Sander C, Schwartz GK, Antonescu CR. 2007. Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. Cancer Res 67: 6626-6636.
32. Snyder EL, Sandstrom DJ, Law K, Fiore C, Sicinska E, Brito J, Bailey D, Fletcher JA, Loda M, Rodig SJ, Dal Cin P, Fletcher CD. 2009. c-Jun amplification and overexpression are oncogenic in liposarcoma but not always sufficient to inhibit the adipocytic differentiation programme. J Pathol 218: 292-300.
33. Tap WD, Eilber FC, Ginther C, Dry SM, Reese N, Barzan-Smith K, Chen HW, Wu H, Eilber FR, Slamon DJ, Anderson L. 2011. Evaluation of well-differentiated/de-differentiated liposarcomas by high-resolution oligonucleotide array-based comparative genomic hybridization. Genes Chromosomes Cancer 50: 95-112.
34. Wang K, Li M, Hadley D, Liu R, Glessner J, Grant SF, Hakonarson H, Bucan M. 2007. PennCNV: An integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. Genome Res 17: 1665-1674.
35. Weiss SW, Goldblum JR. 2008. Enzinger and Weiss's soft tissue tumors, 5th ed. Philadelphia, PA: Mosby Elsevier. p. 477-516.
36. Young A, Lyons J, Miller AL, Phan VT, Alarcón IR, McCormick F. 2009. Ras signaling and therapies. Adv Cancer Res 102: 1-17.